Strangely behaving fluidic oscillator de réir Peszynski K., Tesař V.

Faigh an téacs iomlán

Damage is independent of disease activity in systemic vasculitis de réir McRorie, E, Luqmani, R, Dadoniene, J, Rychlik, I, Tesar, V, Nowack, R

Prospective clinical trial of Gusperimus (deoxyspergualin) in refractory Wegener's granulomatosis de réir Flossmann, O, Baslund, B, Bruchfeld, A, Cohen Tervaert, J, Heinzel, P, Hellmich, B, Luqmani, R, Tesar, V, Jayne, D

Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. de réir Flossmann, O, Baslund, B, Bruchfeld, A, Tervaert, J, Hall, C, Heinzel, P, Hellmich, B, Luqmani, R, Nemoto, K, Tesar, V, Jayne, DR

Evaluating the contribution of the cause of kidney disease to prognosis in CKD: results from the Study of Heart and Renal Protection (SHARP). de réir Haynes, R, Staplin, N, Emberson, J, Herrington, W, Tomson, C, Agodoa, L, Tesar, V, Levin, A, Lewis, D, Reith, C, Baigent, C, Landray, M

Evaluating the contribution of the cause of kidney disease to prognosis in ckd: Results from the Study of Heart and Renal Protection (SHARP) de réir Haynes, R, Staplin, N, Emberson, J, Herrington, W, Tomson, C, Agodoa, L, Tesar, V, Levin, A, Lewis, D, Reith, C, Baigent, C, Landray, M

Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS de réir Jones, R, Tervaert, J, Hauser, T, Luqmani, R, Peh, C, Savage, C, Segelmark, M, Tesar, V, Van Paassen, P, Walsh, M, Walsh, D, Westman, K, Jayne, D

The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. de réir Herrington, W, Emberson, J, Staplin, N, Blackwell, L, Fellström, B, Walker, R, Levin, A, Hooi, L, Massy, Z, Tesar, V, Reith, C, Haynes, R, Baigent, C, Landray, M

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. de réir Jones, R, Tervaert, J, Hauser, T, Luqmani, R, Morgan, MD, Peh, C, Savage, C, Segelmark, M, Tesar, V, van Paassen, P, Walsh, D, Walsh, M, Westman, K, Jayne, DR

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. de réir de Groot, K, Harper, L, Jayne, DR, Flores Suarez, L, Gregorini, G, Gross, W, Luqmani, R, Pusey, C, Rasmussen, N, Sinico, R, Tesar, V, Vanhille, P, Westman, K, Savage, C

Pulse vs daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: a randomized controlled trial de réir Harper, L, De Groot, K, Jayne, D, Flores Suarez, L, Gregorini, G, Gross, W, Luqmani, R, Pusey, C, Rasmussen, N, Sinico, R, Tesar, V, Vanhille, P, Westman, K, Savage, C

Computable phenotype for real-world, data-driven retrospective identification of relapse in ANCA-associated vasculitis de réir Scott, J, White, A, Walsh, C, Aslett, L, Rutherford, MA, Ng, J, Judge, C, Sebastian, K, O’Brien, S, Kelleher, J, Power, J, Conlon, N, Moran, SM, Luqmani, RA, Merkel, PA, Tesar, V, Hruskova, Z, Little, MA

A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. de réir Suppiah, R, Mukhtyar, C, Flossmann, O, Alberici, F, Baslund, B, Batra, R, Brown, D, Holle, J, Hruskova, Z, Jayne, DR, Judge, A, Little, M, Palmisano, A, Stegeman, C, Tesar, V, Vaglio, A, Westman, K, Luqmani, R

Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. de réir Harper, L, Morgan, MD, Walsh, M, Hoglund, P, Westman, K, Flossmann, O, Tesar, V, Vanhille, P, de Groot, K, Luqmani, R, Flores-Suarez, L, Watts, R, Pusey, C, Bruchfeld, A, Rasmussen, N, Blockmans, D, Savage, C, Jayne, D

Measurement of damage in systemic vasculitis: A comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index de réir Suppiah, R, Flossmann, O, Mukhtyar, C, Alberici, F, Baslund, B, Brown, D, Hasan, N, Holle, J, Hruskova, Z, Jayne, D, Judge, A, Little, M, Merkel, P, Palmisano, A, Seo, P, Stegeman, C, Tesar, V, Vaglio, A, Westman, K, Luqmani, R

MEASUREMENT OF DAMAGE IN SYSTEMIC VASCULITIS: A COMPARISON OF THE VASCULITIS DAMAGE INDEX (VDI) WITH THE COMBINED DAMAGE ASSESSMENT INDEX (CDA) de réir Suppiah, R, Flossman, O, Mukhtyar, C, Alberici, F, Baslund, B, Brown, D, Hasan, N, Holle, J, Hruskova, Z, Jayne, D, Judge, A, Little, M, Merkel, P, Palmisano, A, Seo, P, Stegeman, C, Tesar, V, Vaglio, A, Westman, K, Luqmani, R

Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. de réir Suppiah, R, Flossman, O, Mukhtyar, C, Alberici, F, Baslund, B, Brown, D, Hasan, N, Holle, J, Hruskova, Z, Jayne, D, Judge, A, Little, M, Merkel, P, Palmisano, A, Seo, P, Stegeman, C, Tesar, V, Vaglio, A, Westman, K, Luqmani, R

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts de réir Yates, M, Watts, R, Bajema, I, Cid, M, Crestani, B, Hauser, T, Hellmich, B, Holle, J, Laudien, M, Little, MA, Luqmani, RA, Mahr, A, Merkel, P, Mills, J, Mooney, J, Segelmark, M, Tesar, V, Westman, KWA, Vaglio, A, Yalçındağ, N, Jayne, DR, Mukhtyar, C

OP0053 Eular/ERA-EDTA Recommendations for The Management of Anca-Associated Vasculitis de réir Yates, M, Watts, R, Bajema, I, Cid, M, Crestani, B, Hauser, T, Hellmich, B, Holle, J, Laudien, M, Little, M, Luqmani, R, Mahr, A, Merkel, P, Mills, J, Mooney, J, Segelmark, M, Tesar, V, Westman, K, Vaglio, A, Yalçındağ, N, Jayne, D, Mukhtyar, C

EULAR/ERA-EDTA RECOMMENDATIONS FOR THE MANAGEMENT OF ANCA-ASSOCIATED VASCULITIS de réir Yates, M, Watts, R, Nilufer, N, Bajema, I, Little, M, Segelmark, M, Tesar, V, Westman, K, Vaglio, A, Mooney, J, Cid, M, Crestani, B, Hauser, T, Hellmich, B, Holle, J, Laudien, M, Luqmani, R, Mahr, A, Merkel, P, Mills, J, Jayne, D, Mukhtyar, C